**Author details**

Michael John Stones1 \*, Jason Randle2 and Peter Brink1

1 Lakehead University, Thunder Bay, Ontario, Canada

2 University of Waterloo, Waterloo, Ontario, Canada

\*Address all correspondence to: mstones@lakeheadu.ca

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**205**

*Effects of Antipsychotic Medication on Mortality in Long-Term Care Home Residents*

00002

2000;**61**:43-49

treatment of psychosis of Alzheimer's disease: What is the best approach? CNS Drugs. 2007;**21**:101-115 http://dx.doi. org/10.2165/00023210-200721020-

[8] Prakash S, Masand MD. Side effects of antipsychotics in the elderly. The Journal of Clinical Psychiatry.

org/research/digest/nlps/ banerjeereportongeriatric

10.3233/ADR-170042

gps.5106

[11] Randle JM, Heckman G, Oremus M, Ho J. Intermittent antipsychotic medication, and mortality in institutionalized older adults: A scoping review. International Journal of Geriatric Psychiatry. 2019 Jul;**34**(7):906-920. DOI: 10.1002/

[12] Worobetz S. Effects of

archive/0115p12.shtml

[14] Hirdes JP, Poss JW,

Antipsychotic Medications on Older Adults with Dementia in Canadian Complex and Long-Term Care Facilities [Doctoral Thesis]. Thunder Bay: Lakehead University; 2014

[13] Meyer L. Improving medication adherence. Today's geriatric. Medicine. 2015;**8**(1) https://www. todaysgeriatricmedicine.com/

Mitchell L, Korngut L, Heckman G.

[9] Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action. London: Department of Health, UK Government; 2009 Available from: http://psychrights.

[10] Ralph SJ, Espinet AJ. Increased allcause mortality by antipsychotic drugs: Updated review and meta-analysis in dementia and general mental health care. Journal of Alzheimer's Disease Reports. 2018;**2**(1):287-312. DOI:

*DOI: http://dx.doi.org/10.5772/intechopen.95388*

[1] Stones MJ, Worobetz S, Randle J, Marchese C, Fossum S, Ostrom D, et al. Psychotropic medication use and mortality in long-term care residents. In Reynolds, R.J., *Aging – Life Span and Life Expectancy*. London: IntechOpen. . DOI: 10.5572/intechopen.89571 https:// www.intechopen.com/online-first/ psychotropic-medication-use-andmortality-in-long-term-care-residents

[2] Hirdes J, Poss JW, Caldarelli H, Fries BE, Morris JN, Teare GF, et al. An evaluation of data quality in Canada's continuing care reporting system (CCRS): Secondary analyses of Ontario data submitted between 1996 and 2011. BMC Medical Informatics and Decision Making. 2013; 13:27. Available from: http://www.biomedcentral.

com/1472-6947/13/27

[3] Barlas S. Medicare adds new long-term-care pharmacy rules: Agency passes again on pharmacist independence requirements. Pharmacy and Therapeutics. 2016;**41**(12):762-764

[4] Kozman MN, Wattis J,

[5] Cerejeira J, Lagarto L,

10.3389/fneur.2012.00073

[7] Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological

10.1002/hup.745

Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. Human Psychopharmacology: Clinical and Experimental. 2006;**21**(1):1-2. DOI:

Mukaetova-Ladinska E. Behavioral and psychological symptoms of dementia. Frontiers in Neurology. 2012;**3**:73. DOI:

[6] Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;**27**(7):1081- 1090. DOI: 10.1016/j.pnpbp.2003.09.004

**References**

*Effects of Antipsychotic Medication on Mortality in Long-Term Care Home Residents DOI: http://dx.doi.org/10.5772/intechopen.95388*
